Back to resultsEffects of EDP-938 in Hematopoietic Cell Transplant Recipients Who Are Infected With Acute Respiratory Syncytial Virus (RSV) of the Upper Respiratory Tract (RSVTx)
Primary Purpose
Respiratory Syncytial Virus Infections
Status
Recruiting
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
EDP-938
Placebo
Sponsored by
About this trial
This is an interventional treatment trial for Respiratory Syncytial Virus Infections
Eligibility Criteria
Inclusion Criteria:
- Received an autologous HCT (within 6 months of signing ICF) or an allogeneic HCT (any time) using any conditioning regimen
- Absolute lymphocyte count (ALC) <500 cells/ µL in allogeneic HCT recipients. Absolute lymphocyte count (ALC) <300 cells/ µL in autologous HCT recipients.
- Laboratory confirmed RSV diagnosis from a respiratory sample obtained within 3 days before signing the ICF.
- New onset of at least one of the following respiratory symptoms within 3 days before signing the ICF: nasopharyngeal discharge, nasopharyngeal congestion, sneezing, sinus congestion, sore throat, hoarseness, earache, cough, shortness of breath, respiratory wheeze, or worsening of one of these symptoms if present chronically (associated with a previously existing diagnosis [eg, chronic rhinorrhea, chronic lung disease]) in the 3 days before signing the ICF or at Screening.
- No evidence of new abnormalities consistent with LRTI on a chest imaging (chest x-ray and/or computed tomography) performed in the 2 days before signing the ICF or at the Screening visit if there is no chest X-ray and/or computed tomography available in the 2 days before signing the ICF.
- Oxygen saturation >95% on room air.
- A woman of childbearing potential who is sexually active with a male must agree to use two effective methods of contraception from the date of Screening until 30 days after her last dose of study drug.
- A male subject who has not had a vasectomy and is sexually active with a woman of childbearing potential must agree to use effective contraception from the date of Screening to 90 days after his last dose of study drug.
Exclusion Criteria:
- Admitted to the hospital primarily for a lower respiratory tract disease of any cause as determined by the Investigator.
- Known to be concurrently infected with other respiratory viruses (eg, severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] or other coronavirus, influenza, parainfluenza, human rhinovirus, adenovirus, human metapneumovirus) within 7 days before signing the ICF, as determined by local testing.
- Clinically significant viremia, bacteremia, or fungemia, or bacterial or fungal pneumonia within 2 weeks before signing the ICF that has not been adequately treated, as determined by the Investigator.
- Known positive human immunodeficiency virus (HIV).
- Any clinical manifestation resulting in QT prolongation.
Sites / Locations
- Augusta University Medical CenterRecruiting
- Brooke Army Medical Center
- Hospital Universitario Austral
- Hospital Italiano de Buenos Aires
- Fundación FavaloroRecruiting
- Instituto FidesRecruiting
- Sanatorio Allende S.A.Recruiting
- Hospital Britanico de Buenos AiresRecruiting
- Westmead Hospital
- UZ AntwerpenRecruiting
- Institute Jules BordetRecruiting
- Hôpital de JolimontRecruiting
- Chronos Pesquisa ClínicaRecruiting
- Hospital de Clinicas de Porto Alegre (HCPA) - PPDSRecruiting
- Hospital Universitário de Santa MariaRecruiting
- Fundação PIO XIIRecruiting
- Hospital Alemão Oswaldo CruzRecruiting
- Hospital das Clínicas da Faculdade de Medicina da Universidade de São PauloRecruiting
- Toronto General HospitalRecruiting
- Queen Mary HospitalRecruiting
- Centro Medico Imbanaco de Cali S.A.
- Hospital Pablo Tobón UribeRecruiting
- CHU de NiceRecruiting
- Hôtel Dieu -AngersRecruiting
- Hôpital Claude HuriezRecruiting
- Hopital Cote de NacreRecruiting
- Hôpital Saint AntoineRecruiting
- Centre Hospitalier Lyon Sud
- Universitätsmedizin Mannheim
- Universitätsmedizin der Johannes Gutenberg-Universität Mainz
- Attikon University General HospitalRecruiting
- Evangelismos General Hospital of AthensRecruiting
- Rambam Medical CenterRecruiting
- Hadassah Medical CenterRecruiting
- Sheba Medical CenterRecruiting
- Tel Aviv Sourasky Medical CenterRecruiting
- ASST degli Spedali Civili di Brescia - Spedali Civili di Brescia - INCIPIT - PINRecruiting
- Azienda Ospedaliero Universitaria Ospedali Riuniti di Ancona-Umberto I G.M. Lancisi G. SalesiRecruiting
- A.O.U. Maggiore della CaritàRecruiting
- Azienda ULSS 8 "Berica" - Ospedale San BortoloRecruiting
- Azienda Ospedaliera Universitaria CareggiRecruiting
- Fondazione Policlinico Universitario A GemelliRecruiting
- Chungnam National University HospitalRecruiting
- Seoul National University HospitalRecruiting
- The Catholic University of Korea, Seoul St. Mary's HospitalRecruiting
- Samsung Medical CenterRecruiting
- Gachon University Gil Medical CenterRecruiting
- Instituto Nacional de CancerologiaRecruiting
- Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy Oddzial w GliwiRecruiting
- Uniwersyteckie Centrum KliniczneRecruiting
- Samodzielny Publiczny Szpital Kliniczny Nr 1 im. Tadeusza Sokolowskiego Pomorskiego UM w Szczecinie
- Albert Alberts Stem Cell Transplant CentreRecruiting
- FCRN Clinical Trial Centre (Pty) LdtRecruiting
- WITS Clinical Research SiteRecruiting
- Hospital Universitario Son EspasesRecruiting
- ICO l'Hospitalet - Hospital Duran i ReynalsRecruiting
- Hospital de San Pedro de AlcantaraRecruiting
- Hospital Universitario Virgen de La ArrixacaRecruiting
- Hospital Clinic de BarcelonaRecruiting
- Hospital Universitario Virgen de Las NievesRecruiting
- Hospital Universitario Ramon y CajalRecruiting
- Hospital Universitario 12 de OctubreRecruiting
- Hospital Universitario La Paz - PPDSRecruiting
- Hospital General Universitario Morales MeseguerRecruiting
- Hospital Regional Universitario de Malaga - Hospital GeneralRecruiting
- Hospital Universitario Virgen del Rocio - PPDSRecruiting
- Hospital Clinico Universitario de ValenciaRecruiting
- Changhua Christian Medical Foundation Changhua Christian HospitalRecruiting
- Taipei Veterans General HospitalRecruiting
- Ege Universitesi Tip Fakultesi HastanesiRecruiting
- Namik Kemal UniversityRecruiting
- Ondokuz Mayis Universitesi Tip Fakultesi HastanesiRecruiting
- Imperial CollegeRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
EDP-938
Placebo
Arm Description
Outcomes
Primary Outcome Measures
Proportion of subjects who develop Lower Respiratory Tract (LRTC) complication
Secondary Outcome Measures
Change from baseline in RSV RNA viral load
Proportion of Subjects Progressing to Respiratory Failure (of any Cause) Requiring Mechanical Ventilation (Invasive or Noninvasive) or all-cause mortality
Safety as measured by frequency of adverse events (AEs)
Plasma PK Concentrations of EDP-938
Full Information
NCT ID
NCT04633187
First Posted
November 11, 2020
Last Updated
September 12, 2023
Sponsor
Enanta Pharmaceuticals, Inc
1. Study Identification
Unique Protocol Identification Number
NCT04633187
Brief Title
Effects of EDP-938 in Hematopoietic Cell Transplant Recipients Who Are Infected With Acute Respiratory Syncytial Virus (RSV) of the Upper Respiratory Tract
Acronym
RSVTx
Official Title
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Effects of EDP-938 in Hematopoietic Cell Transplant Recipients With Acute Respiratory Syncytial Virus Infection of the Upper Respiratory Tract
Study Type
Interventional
2. Study Status
Record Verification Date
July 2023
Overall Recruitment Status
Recruiting
Study Start Date
July 7, 2021 (Actual)
Primary Completion Date
April 2024 (Anticipated)
Study Completion Date
April 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Enanta Pharmaceuticals, Inc
4. Oversight
Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
This is a Phase 2b, randomized, double-blind, placebo-controlled, multicenter study evaluating the efficacy and safety of EDP-938 in HCT recipients with acute RSV infection and symptoms of URTI.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Respiratory Syncytial Virus Infections
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
200 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
EDP-938
Arm Type
Experimental
Arm Title
Placebo
Arm Type
Placebo Comparator
Intervention Type
Drug
Intervention Name(s)
EDP-938
Intervention Description
EDP-938 800mg
Dose adjustments will be made for subjects taking azole antifungals.
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Subjects will take EDP-938 matching placebo tablets once a day orally for 21 days
Primary Outcome Measure Information:
Title
Proportion of subjects who develop Lower Respiratory Tract (LRTC) complication
Time Frame
Day 1 through Day 28
Secondary Outcome Measure Information:
Title
Change from baseline in RSV RNA viral load
Time Frame
Day 1 through Day 49
Title
Proportion of Subjects Progressing to Respiratory Failure (of any Cause) Requiring Mechanical Ventilation (Invasive or Noninvasive) or all-cause mortality
Time Frame
Day 1 through Day 49
Title
Safety as measured by frequency of adverse events (AEs)
Time Frame
Day 1 through Day 49
Title
Plasma PK Concentrations of EDP-938
Time Frame
Day 0 through Day 21
10. Eligibility
Sex
All
Minimum Age & Unit of Time
16 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Received an autologous HCT (within 6 months of signing ICF) or an allogeneic HCT (any time) using any conditioning regimen
Absolute lymphocyte count (ALC) <500 cells/ µL in allogeneic HCT recipients. Absolute lymphocyte count (ALC) <300 cells/ µL in autologous HCT recipients.
Laboratory confirmed RSV diagnosis from a respiratory sample obtained within 3 days before signing the ICF.
New onset of at least one of the following respiratory symptoms within 3 days before signing the ICF: nasopharyngeal discharge, nasopharyngeal congestion, sneezing, sinus congestion, sore throat, hoarseness, earache, cough, shortness of breath, respiratory wheeze, or worsening of one of these symptoms if present chronically (associated with a previously existing diagnosis [eg, chronic rhinorrhea, chronic lung disease]) in the 3 days before signing the ICF or at Screening.
No evidence of new abnormalities consistent with LRTI on a chest imaging (chest x-ray and/or computed tomography) performed in the 2 days before signing the ICF or at the Screening visit if there is no chest X-ray and/or computed tomography available in the 2 days before signing the ICF.
Oxygen saturation >95% on room air.
A woman of childbearing potential who is sexually active with a male must agree to use two effective methods of contraception from the date of Screening until 30 days after her last dose of study drug.
A male subject who has not had a vasectomy and is sexually active with a woman of childbearing potential must agree to use effective contraception from the date of Screening to 90 days after his last dose of study drug.
Exclusion Criteria:
Admitted to the hospital primarily for a lower respiratory tract disease of any cause as determined by the Investigator.
Known to be concurrently infected with other respiratory viruses (eg, severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] or other coronavirus, influenza, parainfluenza, human rhinovirus, adenovirus, human metapneumovirus) within 7 days before signing the ICF, as determined by local testing.
Clinically significant viremia, bacteremia, or fungemia, or bacterial or fungal pneumonia within 2 weeks before signing the ICF that has not been adequately treated, as determined by the Investigator.
Known positive human immunodeficiency virus (HIV).
Any clinical manifestation resulting in QT prolongation.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Enanta Pharmaceuticals, Inc
Phone
(617) 607-0800
Email
charris@enanta.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Enanta Pharmaceuticals, Inc
Organizational Affiliation
Enanta Pharmaceuticals, Inc
Official's Role
Study Director
Facility Information:
Facility Name
Augusta University Medical Center
City
Augusta
State/Province
Georgia
ZIP/Postal Code
30912
Country
United States
Individual Site Status
Recruiting
Facility Name
Brooke Army Medical Center
City
Fort Sam Houston
State/Province
Texas
ZIP/Postal Code
78234
Country
United States
Individual Site Status
Withdrawn
Facility Name
Hospital Universitario Austral
City
Pilar
State/Province
Buenos Aires
ZIP/Postal Code
B1629AHJ
Country
Argentina
Individual Site Status
Withdrawn
Facility Name
Hospital Italiano de Buenos Aires
City
Buenos Aires
State/Province
Ciudad Autónoma De BuenosAires
ZIP/Postal Code
1199ABB
Country
Argentina
Individual Site Status
Withdrawn
Facility Name
Fundación Favaloro
City
Buenos Aires
State/Province
Ciudad Autónoma De BuenosAires
ZIP/Postal Code
C1093AAS
Country
Argentina
Individual Site Status
Recruiting
Facility Name
Instituto Fides
City
La Plata
State/Province
Ciudad Autónoma De BuenosAires
ZIP/Postal Code
483 5051
Country
Argentina
Individual Site Status
Recruiting
Facility Name
Sanatorio Allende S.A.
City
Córdoba
State/Province
Cordoba
ZIP/Postal Code
X5000JHQ
Country
Argentina
Individual Site Status
Recruiting
Facility Name
Hospital Britanico de Buenos Aires
City
Buenos Aires
ZIP/Postal Code
C1280AEB
Country
Argentina
Individual Site Status
Recruiting
Facility Name
Westmead Hospital
City
Westmead
State/Province
New South Wales
ZIP/Postal Code
2145
Country
Australia
Individual Site Status
Withdrawn
Facility Name
UZ Antwerpen
City
Edegem
State/Province
Antwerpen
ZIP/Postal Code
2650
Country
Belgium
Individual Site Status
Recruiting
Facility Name
Institute Jules Bordet
City
Anderlecht
State/Province
Brussels
ZIP/Postal Code
1070
Country
Belgium
Individual Site Status
Recruiting
Facility Name
Hôpital de Jolimont
City
La Louvière
ZIP/Postal Code
7100
Country
Belgium
Individual Site Status
Recruiting
Facility Name
Chronos Pesquisa Clínica
City
Brasília
State/Province
Distrito Federal
ZIP/Postal Code
72145-450
Country
Brazil
Individual Site Status
Recruiting
Facility Name
Hospital de Clinicas de Porto Alegre (HCPA) - PPDS
City
Porto Alegre
State/Province
Rio Grande Do Sul
ZIP/Postal Code
90035
Country
Brazil
Individual Site Status
Recruiting
Facility Name
Hospital Universitário de Santa Maria
City
Santa Maria
State/Province
Rio Grande Do Sul
ZIP/Postal Code
97105-900
Country
Brazil
Individual Site Status
Recruiting
Facility Name
Fundação PIO XII
City
Barretos
State/Province
Sao Paulo
ZIP/Postal Code
14784
Country
Brazil
Individual Site Status
Recruiting
Facility Name
Hospital Alemão Oswaldo Cruz
City
São Paulo
State/Province
Sao Paulo
ZIP/Postal Code
01323-903
Country
Brazil
Individual Site Status
Recruiting
Facility Name
Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
City
São Paulo
State/Province
Sao Paulo
ZIP/Postal Code
05403000
Country
Brazil
Individual Site Status
Recruiting
Facility Name
Toronto General Hospital
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M5G 2C4
Country
Canada
Individual Site Status
Recruiting
Facility Name
Queen Mary Hospital
City
Hong Kong
State/Province
Hong Kong
Country
China
Individual Site Status
Recruiting
Facility Name
Centro Medico Imbanaco de Cali S.A.
City
Cali
State/Province
Valle Del Cauca
Country
Colombia
Individual Site Status
Withdrawn
Facility Name
Hospital Pablo Tobón Uribe
City
Medellín
Country
Colombia
Individual Site Status
Recruiting
Facility Name
CHU de Nice
City
Nice
State/Province
Alpes-Maritimes
ZIP/Postal Code
06202
Country
France
Individual Site Status
Recruiting
Facility Name
Hôtel Dieu -Angers
City
Angers
State/Province
Maine-et-Loire
ZIP/Postal Code
49933
Country
France
Individual Site Status
Recruiting
Facility Name
Hôpital Claude Huriez
City
Lille
State/Province
Nord
ZIP/Postal Code
59037
Country
France
Individual Site Status
Recruiting
Facility Name
Hopital Cote de Nacre
City
Caen
ZIP/Postal Code
14000
Country
France
Individual Site Status
Recruiting
Facility Name
Hôpital Saint Antoine
City
Paris
ZIP/Postal Code
75012
Country
France
Individual Site Status
Recruiting
Facility Name
Centre Hospitalier Lyon Sud
City
Pierre-Bénite
Country
France
Individual Site Status
Withdrawn
Facility Name
Universitätsmedizin Mannheim
City
Mannheim
State/Province
Baden-Württemberg
ZIP/Postal Code
68167
Country
Germany
Individual Site Status
Withdrawn
Facility Name
Universitätsmedizin der Johannes Gutenberg-Universität Mainz
City
Mainz
State/Province
Rheinland-Pfalz
ZIP/Postal Code
55131
Country
Germany
Individual Site Status
Withdrawn
Facility Name
Attikon University General Hospital
City
Athens
Country
Greece
Individual Site Status
Recruiting
Facility Name
Evangelismos General Hospital of Athens
City
Athens
Country
Greece
Individual Site Status
Recruiting
Facility Name
Rambam Medical Center
City
Haifa
ZIP/Postal Code
31096
Country
Israel
Individual Site Status
Recruiting
Facility Name
Hadassah Medical Center
City
Jerusalem
ZIP/Postal Code
91120
Country
Israel
Individual Site Status
Recruiting
Facility Name
Sheba Medical Center
City
Ramat Gan
ZIP/Postal Code
52621
Country
Israel
Individual Site Status
Recruiting
Facility Name
Tel Aviv Sourasky Medical Center
City
Tel Aviv
ZIP/Postal Code
64239
Country
Israel
Individual Site Status
Recruiting
Facility Name
ASST degli Spedali Civili di Brescia - Spedali Civili di Brescia - INCIPIT - PIN
City
Brescia
State/Province
Lombardia
ZIP/Postal Code
25123
Country
Italy
Individual Site Status
Recruiting
Facility Name
Azienda Ospedaliero Universitaria Ospedali Riuniti di Ancona-Umberto I G.M. Lancisi G. Salesi
City
Ancona
State/Province
Marche
ZIP/Postal Code
60020
Country
Italy
Individual Site Status
Recruiting
Facility Name
A.O.U. Maggiore della Carità
City
Novara
State/Province
Piemonte
ZIP/Postal Code
28100
Country
Italy
Individual Site Status
Recruiting
Facility Name
Azienda ULSS 8 "Berica" - Ospedale San Bortolo
City
Vicenza
State/Province
Veneto
ZIP/Postal Code
36100
Country
Italy
Individual Site Status
Recruiting
Facility Name
Azienda Ospedaliera Universitaria Careggi
City
Firenze
ZIP/Postal Code
50134
Country
Italy
Individual Site Status
Recruiting
Facility Name
Fondazione Policlinico Universitario A Gemelli
City
Roma
ZIP/Postal Code
00168
Country
Italy
Individual Site Status
Recruiting
Facility Name
Chungnam National University Hospital
City
Daejeon
ZIP/Postal Code
301-721
Country
Korea, Republic of
Individual Site Status
Recruiting
Facility Name
Seoul National University Hospital
City
Seoul
ZIP/Postal Code
03080
Country
Korea, Republic of
Individual Site Status
Recruiting
Facility Name
The Catholic University of Korea, Seoul St. Mary's Hospital
City
Seoul
ZIP/Postal Code
06591
Country
Korea, Republic of
Individual Site Status
Recruiting
Facility Name
Samsung Medical Center
City
Seoul
Country
Korea, Republic of
Individual Site Status
Recruiting
Facility Name
Gachon University Gil Medical Center
City
Ulsan
ZIP/Postal Code
682714
Country
Korea, Republic of
Individual Site Status
Recruiting
Facility Name
Instituto Nacional de Cancerologia
City
Mexico City
ZIP/Postal Code
14080
Country
Mexico
Individual Site Status
Recruiting
Facility Name
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy Oddzial w Gliwi
City
Gliwice
State/Province
Slaskie
Country
Poland
Individual Site Status
Recruiting
Facility Name
Uniwersyteckie Centrum Kliniczne
City
Gdańsk
Country
Poland
Individual Site Status
Recruiting
Facility Name
Samodzielny Publiczny Szpital Kliniczny Nr 1 im. Tadeusza Sokolowskiego Pomorskiego UM w Szczecinie
City
Szczecin
Country
Poland
Individual Site Status
Withdrawn
Facility Name
Albert Alberts Stem Cell Transplant Centre
City
Pretoria
State/Province
Gauteng
ZIP/Postal Code
0044
Country
South Africa
Individual Site Status
Recruiting
Facility Name
FCRN Clinical Trial Centre (Pty) Ldt
City
Vereeniging
State/Province
Gauteng
ZIP/Postal Code
1935
Country
South Africa
Individual Site Status
Recruiting
Facility Name
WITS Clinical Research Site
City
Johannesburg
Country
South Africa
Individual Site Status
Recruiting
Facility Name
Hospital Universitario Son Espases
City
Palma De Mallorca
State/Province
Baleares
ZIP/Postal Code
07010
Country
Spain
Individual Site Status
Recruiting
Facility Name
ICO l'Hospitalet - Hospital Duran i Reynals
City
L'Hospitalet De Llobregat
State/Province
Barcelona
ZIP/Postal Code
08908
Country
Spain
Individual Site Status
Recruiting
Facility Name
Hospital de San Pedro de Alcantara
City
Cáceres
State/Province
Caceres
ZIP/Postal Code
10003
Country
Spain
Individual Site Status
Recruiting
Facility Name
Hospital Universitario Virgen de La Arrixaca
City
El Palmar
State/Province
Murcia
ZIP/Postal Code
30120
Country
Spain
Individual Site Status
Recruiting
Facility Name
Hospital Clinic de Barcelona
City
Barcelona
ZIP/Postal Code
08036
Country
Spain
Individual Site Status
Recruiting
Facility Name
Hospital Universitario Virgen de Las Nieves
City
Granada
ZIP/Postal Code
18014
Country
Spain
Individual Site Status
Recruiting
Facility Name
Hospital Universitario Ramon y Cajal
City
Madrid
ZIP/Postal Code
28034
Country
Spain
Individual Site Status
Recruiting
Facility Name
Hospital Universitario 12 de Octubre
City
Madrid
ZIP/Postal Code
28041
Country
Spain
Individual Site Status
Recruiting
Facility Name
Hospital Universitario La Paz - PPDS
City
Madrid
ZIP/Postal Code
28046
Country
Spain
Individual Site Status
Recruiting
Facility Name
Hospital General Universitario Morales Meseguer
City
Murcia
ZIP/Postal Code
30008
Country
Spain
Individual Site Status
Recruiting
Facility Name
Hospital Regional Universitario de Malaga - Hospital General
City
Málaga
ZIP/Postal Code
29010
Country
Spain
Individual Site Status
Recruiting
Facility Name
Hospital Universitario Virgen del Rocio - PPDS
City
Sevilla
ZIP/Postal Code
41013
Country
Spain
Individual Site Status
Recruiting
Facility Name
Hospital Clinico Universitario de Valencia
City
Valencia
ZIP/Postal Code
46026
Country
Spain
Individual Site Status
Recruiting
Facility Name
Changhua Christian Medical Foundation Changhua Christian Hospital
City
Changhua
ZIP/Postal Code
50006
Country
Taiwan
Individual Site Status
Recruiting
Facility Name
Taipei Veterans General Hospital
City
Taipei City
Country
Taiwan
Individual Site Status
Recruiting
Facility Name
Ege Universitesi Tip Fakultesi Hastanesi
City
Bornova
State/Province
Izmir
Country
Turkey
Individual Site Status
Recruiting
Facility Name
Namik Kemal University
City
Tekirdağ
State/Province
Tekirdag
Country
Turkey
Individual Site Status
Recruiting
Facility Name
Ondokuz Mayis Universitesi Tip Fakultesi Hastanesi
City
Samsun
Country
Turkey
Individual Site Status
Recruiting
Facility Name
Imperial College
City
London
ZIP/Postal Code
W12 0HS
Country
United Kingdom
Individual Site Status
Recruiting
12. IPD Sharing Statement
Learn more about this trial
Effects of EDP-938 in Hematopoietic Cell Transplant Recipients Who Are Infected With Acute Respiratory Syncytial Virus (RSV) of the Upper Respiratory Tract
We'll reach out to this number within 24 hrs